Other substances

Cenicriviroc

A chemokine receptor antagonist.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
2
 Clinical trials

General information

Cenicriviroc is a chemokine 2 and 5 receptor antagonist with anti-HIV, antirheumatic and anti-inflammatory properties (ChEBI).

Cenicriviroc on DrugBank
Cenicriviroc on PubChem
Cenicriviroc on Wikipedia

 

Structure image - Cenicriviroc

CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C

Supporting references

Link Tested on Impact factor Notes Publication date
The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro
VERO E6 cells expressing TMPRSS2 4.10

The compound reduced viral RNA and viral antigen levels, decreased cytopathic effect of the virus. Mechanism of action not known, other studies demonstrated anti-inflamatory activity in vivo.

 Jul/30/2020

AI-suggested references

Link Publication date
QSAR Modeling of SARS-CoV Mpro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2.
Aug/24/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04500418 Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Recruiting Phase 2 Aug/25/2020 Sep/30/2021
  • Alternative id - CVC for COVID-19|2020-001493-29
  • Interventions - Drug: Cenicriviroc (CVC)|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Medical Department of Hepatology and Gastroenterology, Charité University Medicine, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 183
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Subject´s Responder status (score on the 7-point ordinal scale on Day 15)|Evaluation of change in clinical condition based on the 7-point ordinal scale|Evaluation of change in clinical condition based on the 7-point ordinal scale and Responder Status|Hospital resource utilization comparison
NCT04593940 Immune Modulators for Treating COVID-19 Completed Phase 3 Oct/15/2020 Mar/05/2022
  • Alternative id - Pro00106301
  • Interventions - Drug: Infliximab|Drug: Abatacept|Drug: Remdesivir|Drug: cenicriviroc (closed to enrollment as of 3-Sep-2021)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Banner University Medical Center, Phoenix, Arizona, United States|University of Arkansas Medical Sciences, Little Rock, Arkansas, United States|Scripps Clinical Medical Group, La Jolla, California, United States|UCLA - Ronald Reagan Medical Center, Los Angeles, California, United States|Riverside University, Moreno Valley, California, United States|UC Irvine Medical Center, Orange, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCLA Medical Center- Santa Monica, Santa Monica, California, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|University of Florida-Jacksonville, Jacksonville, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Tulane School of Medicine, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|U Mass Memorial Medical Center, Worcester, Massachusetts, United States|U Mass University Medical Center, Worcester, Massachusetts, United States|MidMichigan Medical Center- Gratiot, Alma, Michigan, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri Health Care, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Trinitas Hospital, Elizabeth, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers New Jersey Medical School, New Brunswick, New Jersey, United States|NYU Brooklyn, Brooklyn, New York, United States|University at Buffalo, Buffalo, New York, United States|Flushing Hospital Medical Center, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|NYU Long Island, Long Island City, New York, United States|New York University Langone Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|St Lawrence Health System, Potsdam, New York, United States|University of Rochester Medical Center-Strong Memorial Hospital, Rochester, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Mercy Saint Vincent Medical Center, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Reading Hospital Study, Wyomissing, Pennsylvania, United States|Avera McKennan Hospital, Sioux Falls, South Dakota, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Methodist Health System Clinical Research Institute, Dallas, Texas, United States|University of Texas Health Science Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Trinity Mother Frances Hospital, Tyler, Texas, United States|University of Texas Health Center at Tyler, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Providence Medical Research Center, Spokane, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Gundersen Health System, La Crosse, Wisconsin, United States|Hospital Interzonal Dr Jose Penna Bahia Blanca, Bahía Blanca, Buenos Aires, Argentina|Sanatorio Ramon Cereijo, Caba, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Clinica Central S.A., Villa Regina, Rio Negro, Argentina|Hospital Ramos Mejia, Buenos Aires, Argentina|Hospital Rawson, Cordoba, Argentina|Sanatorio Allende, Córdoba, Argentina|Sanatorio Britanico, Rosario, Argentina|Sanatorio Diagnóstico/ Instituto del Buen Aire, Santa Fe, Argentina|Hospital Brasília, Brasília, DF, Brazil|Hospital Felício Rocho, Belo Horizonte, MG, Brazil|Instituto DOR de Ensino e Pesquisa Hospital Glória D'Or, Rio De Janeiro, Rio De Janeiro / RJ, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Rio Grande D Sul /RS, Brazil|Hospital de Clinicas de Porto Alegre HCPA, Porto Alegre, Rio Grande Do Sul / RS, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul/RS, Brazil|Hospital e Maternidade Celso Pierro - PUC Campinas, Campinas, São Paulo/SP, Brazil|Nuevo Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, Guadalajara Jalisco, Mexico|Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Nuevo León, Monterrey, Mexico|Hospital Central FAP, Lima, Lima/Lima, Peru|Hospital Regional Lambayeque, Chiclayo, Peru|Hospitala Nacional Hipólito Unánue, Lima, Peru|Hospital Nacional Aezobispo Loayza, Lima, Peru|Hospital de Chancay y Servicios Basicos de Salud, Lima, Peru|Clínica Belén SANNA, Piura, Peru
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1971
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients that recovered from COVID-19|Change in number of patients hospitalized on invasive mechanical ventilation|number of patients that improved clinically|Number of patient deaths|Number of patients with decreased supplemental oxygenation needed|Change in number of patients needing non-invasive ventilation/ high flow oxygen|Number of days patients are in the hospital|Number of SAEs and AEs of grade 3 and 4|Number of patients with changes in abnormal WBC counts
Export (.csv)